Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 127Squamous Cell Carcinoma of Head and Neck 64Melanoma 64Parkinson Disease 4, Autosomal Dominant Lewy Body 53Lung Neoplasms 50Triple Negative Breast Neoplasms 47Neoplasm Metastasis 46Breast Neoplasms 42Neoplasms 38Colorectal Neoplasms 33Carcinoma, Renal Cell 30Head and Neck Neoplasms 28Endometrial Neoplasms 28Ovarian Neoplasms 27Carcinoma, Transitional Cell 23Urinary Bladder Neoplasms 21Stomach Neoplasms 17Pancreatic Neoplasms 15Carcinoma 15Uterine Cervical Neoplasms 13Brain Neoplasms 13Recurrence 12Esophageal Neoplasms 12Sarcoma 11Hodgkin Disease 11Carcinoma, Squamous Cell 11Carcinoma, Hepatocellular 11Cholangiocarcinoma 10Skin Neoplasms 9Esophageal Squamous Cell Carcinoma 9

Interventions

pembrolizumab 1osimertinib 1cemiplimab 1Vascular Endothelial Growth Factor A 1Paroxetine 1Paclitaxel 1Itraconazole 1Docetaxel 1Carboplatin 1Antibodies, Bispecific 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lethal Congenital Contracture Syndrome 2 × pembrolizumab × 90 days × Clear all
NCT07111520 2026-05-05

A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)

BioNTech SE

Phase 1/2 Recruiting
420 enrolled
Thoracic

Lethal Congenital Contracture Syndrome 2, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡